IDH-mutant glioma
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
7 of 9 arms with a reported figure. Choose arms to narrow the chart.
months 6
Vorasidenib 40 mg. median PFS, vorasidenib: 27.7 months, NEJM 2023
Vorasidenib 40 mg. median PFS, placebo: 11.1 months, NEJM 2023
Vorasidenib 40 mg. median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminary
Vorasidenib Phase 1 doses. median PFS: 36.8 months, Phase 1
Ivosidenib Phase 1 doses. median PFS: 13.6 months, 95% CI 9.2 to 33.2
Olaparib 300 mg. median PFS: 2.05 months
Bars in this group share the unit months. 44.1 months is the longest reported value here. A different unit is not redrawn onto this scale.
% 3
Safusidenib (AB-218, DS-1001) 250 mg. 36-month PFS rate: 79.1%, median follow-up 38.8 months
IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in source. 3-year PFS rate: 63%
Olaparib 300 mg. 6-month PFS rate: 31.4%, primary endpoint, target 50% not met
Bars in this group share the unit %. 79.1 % is the longest reported value here. A different unit is not redrawn onto this scale.
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.